2024

Bhuria V, Franz T, Baldauf C, Böttcher M, Chatain N, Koschmieder S, Brümmendorf TH, Mougiakakos D, Schraven B, Kahlfuß S, Fischer T.
Activating mutations in JAK2 and CALR differentially affect intracellular calcium flux in store operated calcium entry.
Cell Commun Signal. 2024 Mar 21;22(1):186. doi: 10.1186/s12964-024-01530-z.

2023

Baur R, Karl F, Böttcher-Loschinski R, Stoll A, Völkl S, Gießl A, Flamann C, Bruns H, Schlötzer-Schrehardt U, Böttcher M, Schewe DM, Fischer T, Jitschin R, Mackensen A, Mougiakakos D.
Accumulation of T-cell-suppressive PD-L1high extracellular vesicles is associated with GvHD and might impact GvL efficacy.
J Immunother Cancer. 2023 Mar;11(3):e006362.

Haage TR, Schraven B, Mougiakakos D, Fischer T.
How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia.
Cancers (Basel). 2023 May 30;15(11):2991.

Karl F, Liang C, Böttcher-Loschinski R, Stoll A, Flamann C, Richter S, Lischer C, Völkl S, Jacobs B, Böttcher M, Jitschin R, Bruns H, Fischer T, Holler E, Rösler W, Dandekar T, Mackensen A, Mougiakakos D.
Oxidative DNA damage in reconstituting T cells is associated with relapse and inferior survival after allo-SCT.
Blood. 2023 Mar 30;141(13):1626-1639.

Massacci G, Venafra V, Latini S, Bica V, Pugliese GM, Graziosi S, Klingelhuber F, Krahmer N, Fischer T, Mougiakakos D, Boettcher M, Perfetto L, Sacco F.
A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients.
Leukemia. 2023 Feb;37(2):288-297.

Pugliese GM, Venafra V, Bica V, Massacci G, Latini S, Graziosi S, Fischer T, Mougiakakos D, Boettcher M, Perfetto L, Sacco F.
Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach.
Leukemia. 2023 May;37(5):1151-1155.

Reimann AM, Schalk E, Jost F, Mougiakakos D, Weber D, Döhner H, Récher C, Dumas PY, Ditzhaus M, Fischer T, Sager S.
AML consolidation therapy: timing matters.
J Cancer Res Clin Oncol. 2023 Nov;149(15):13811-13821.

2022

Baldauf CK, Müller P, Haage TR, Adam-Frey S, Lokau J, Garbers C, Fischer T.
Anti-IL-6 cytokine treatment has no impact on elevated hematocrit or splenomegaly in a polycythemia vera mouse model.
Blood Adv. 2022 Jan 25;6(2):399-404. doi: 10.1182/bloodadvances.2021004379.

Bhuria V, Baldauf CK, Schraven B, Fischer T.
Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved.
Int J Mol Sci. 2022 Mar 16;23(6):3206. doi: 10.3390/ijms23063206.

Müller P, Baldauf CK, Haage TR, Charakopoulos E, Böttcher M, Bhuria V, Mougiakakos D, Schraven B, Fischer T.
Genetic Knock-out of TNFR1 and TNFR2 in a JAK2-V617F Polycythemia Vera Mouse Model.
Hemasphere. 2022 Apr 15;6(5):e717.

Rücker FG, Du L, Luck TJ, Benner A, Krzykalla J, Gathmann I, Voso MT, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Savoie L, Sierra J, Pallaud C, Sanz MA, Jansen JH, Niederwieser D, Fischer T, Ehninger G, Heuser M, Ganser A, Bullinger L, Larson RA, Bloomfield CD, Stone RM, Döhner H, Thiede C, Döhner K.
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.
Leukemia. 2022 Jan;36(1):90-99.

Tettero JM, Al-Badri WKW, Ngai LL, Bachas C, Breems DA, van Elssen CHMJ, Fischer T, Gjertsen BT, van Gorkom GNY, Gradowska P, Greuter MJE, Griskevicius L, Juliusson G, Maertens J, Manz MG, Pabst T, Passweg J, Porkka K, Löwenberg B, Ossenkoppele GJ, Janssen JJWM, Cloos J.
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis.
Front Oncol. 2022 Oct 10;12:999822.

2021

Dudeck J, Kotrba J, Immler R, Hoffmann A, Voss M, Alexaki VI , Morton L, Jahn SR, Katsoulis-Dimitriou K, Winzer S, Kollias Georg, Fischer T, Nedospasov SA, Dunay IR, Chavakis T, Müller A J, Schraven B, Sperandio M, Dudeck A.
Directional mast cell degranulation of tumor necrosis factor into blood vessels primes neutrophil extravasation.
Immunity, 2021; Mar 9;54(3):468-483.e5. doi: 10.1016/j.immuni.2020.12.017. Epub 2021 Jan 22. Imp.-Fact.:22,553

Müller P, Baldauf CK, Haage TR, Waldleben AM, Richter F, Pfizenmaier K, Fischer T.
Anti-inflammatory treatment in MPN: Targeting TNFα-receptor 1 (TNFR1) and TNFR2 in JAK2-V617F induced disease.
Blood Adv. 2021 Sep 30:bloodadvances.2021004438. doi: 10.1182/bloodadvances.2021004438. Online ahead of print. Imp.-Fact.: 6,686

Osbelt L, Wende M, Almási E, Derksen E, Muthukumarasamy U, Lesker TR, Galvez EJC, Pils MC, Schalk E, Chhatwal P, Färber J, Neumann-Schaal M, Fischer T, Schlüter D, Strowig T.
Klebsiella oxytoca causes colonization resistance against multidrug-resistant K. pneumoniae in the gut via cooperative carbohydrate competition.
Cell Host Microbe 2021; 2021 Sep 29;S1931-3128(21)00419-4. doi: 10.1016/j.chom.2021.09.003. Online ahead of print. Imp.-Fact.:21,023

2020

Jost F, Schalk E, Weber D, Doehner H, Fischer T, Sager S.
Model-based optimal AML consolidation treatment.
IEEE Trans Biomed Eng 2020;67(12):3296-3306. Imp.-Fact.:4,424

Lilienthal P, Tetschke M, Schalk E, Fischer T, Sager S.
Optimized and personalized phlebotomy schedules for patients suffering from polycythemia vera.
Front Physiol 2020;11:328. Imp.-Fact.:3,2

Rummelt C, Gorantla SP, Meggendorfer M, Charlet A, Endres C, Döhner K, Heidel FH, Fischer T, Haferlach T, Duyster J, von Bubnoff N.
Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo.
Leukemia. 2020 Nov 4. Imp.-Fact.:8,665

2019

Hillert LK, Bettermann-Bethge K, Nimmagadda SC, Fischer T, Naumann M, Lavrik IN.
Targeting RIPK1 in AML cells carrying FLT3-ITD.
Int J Cancer. 2019 Mar 3. [Epub ahead of print] Imp.-Fact.:7,36

Jost F, Schalk E, Rinke K, Fischer T, Sager S.
Mathematical models for cytarabine-derived myelosuppression in acute myeloid leukaemia.
PLoS One 2019;14(7):e0204540. Imp.-Fact.:2,806

Lowinus T, Heidel FH, Bose T, Nimmagadda SC, Schnöder T, Cammann C, Schmitz I, Seifert U, Fischer T, Schraven B, Bommhardt U.
Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling.
Cell Commun Signal. 2019 Jan 16;17(1):5. Imp.-Fact.:5,324

Nimmagadda SC, Frey S, Müller P, Wolleschak D, Weinert S, Keller U, Edelmann B, Fischer T.
SDF1a-induced chemotaxis of JAK2-V617F positive cells is dependent on Bruton's Tyrosine Kinase and its downstream targets PI3K/AKT, PLC gamma 1 and RhoA.
Haematologica. 2019 Jul;104(7):e288-e292. Imp.-Fact.:9,09

2018

Edelmann B, Gupta N, Schnöder T, Oelschlegel AM, Shahzad K, Goldschmidt J, Philipsen L, Weinert S, Ghosh A, Saalfeld FC , Nimmagadda SC, Müller P, Braun-Dullaeus RC, Mohr J, Wolleschak D, Kliche S, Amthauer H, Heidel F, Schraven B, Isermann B, Müller AJ, Fischer T.
JAK2-V617F promotes venous thrombosis through ß1/ß2 integrin activation.
J Clin Invest. 2018;128(10):4359-4371. Imp.-Fact.:13,25

Lilienthal P, Tetschke M, Pottgiesser T, Fischer T, Schalk E, Sager S.
Mathematical Modeling of RBC count dynamics after blood loss.
Processes 2018;6(9):157. Imp.-Fact.:1,279

Maifrede S, Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik M, Huang J, Skorski T.
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Blood. 2018 May 21. pii: blood-2018-02-834895.[Epub ahead of print] Imp.-Fact.:13,164

Marhäll A, Heidel F, Fischer T, Rönnstrand L.
Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
Ann Hematol. 2018 May;97(5):773-780. Imp.-Fact.:3,083

2017

Arra A, Lingel H, Kuropka B, Pick J, Schnoeder T, Fischer T, Freund C, Pierau M, Brunner-Weinzierl MC.
The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs.
Oncoimmunology. 2017 Jan 20;6(2):e1273300. Imp.-Fact.:7,719

Bongartz H, Hessenkemper W, Müller C, Fensky M, Fritsch J, Mandel K, Behrmann I, Haan C, Fischer T, Feller SM, Schaper F.
The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells.
Cell Signal. 2017 Jul;35:37-47. Imp.-Fact.:3,937

Gieseler-Halbach S, Meltendorf S, Pierau M, Weinert S, Heidel FH, Fischer T, Handschuh J, Braun-Dullaeus RC, Schrappe M, Lindquist JA, Mertens PR, Thomas U, Brunner-Weinzierl MC.
RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts.
Cell Death Differ. 2017 Feb;24(2):371-383. Epub 2016 Dec 23. Imp.-Fact.:8,339

Gupta N, Edelmann B, Schnoeder TM, Saalfeld FC, Wolleschak D, Kliche S, Schraven B, Heidel FH, Fischer T.
JAK2-V617F activates ß1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1.
Leukemia. 2017 May;31(5):1223-1226. Epub 2017 Jan 18. Imp.-Fact.:10,023

Nishanth G, Wolleschak D, Fahldieck C, Fischer T, Mullally A, Perner F, Schnöder TM, Just S, Heidel FH, Schlüter D.
Gain of function in Jak2V617F-positive T-cells.
Leukemia. 2017 Apr;31(4):1000-1003. Imp.-Fact.:10,023

Ranjan S, Goihl A, Kohli S, Gadi I, Pierau M, Shahzad K, Gupta D, Bock F, Wang H, Shaikh H, Kähne T, Reinhold D, Bank U, Zenclussen AC, Niemz J, Schnöder TM, Brunner-Weinzierl M, Fischer T, Kalinski T, Schraven B, Luft T, Huehn J, Naumann M, Heidel FH, Isermann B.
Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells.
Nat Commun. 2017 Aug 21;8(1):311. Imp.-Fact.:12,124

Schnöder TM, Eberhardt J, Koehler M, Bierhoff HB, Weinert S, Pandey AD, Nimmagadda SC, Wolleschak D, Jöhrens K, Fischer T, Heidel FH.
Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.
J Cancer Res Clin Oncol. 2017 May;143(5):807-820. Imp.-Fact.:3,503

2016

Arreba-Tutusaus P, Mack TS, Bullinger L, Schnöder TM, Polanetzki A, Weinert S, Ballaschk A, Wang Z, Deshpande AJ, Armstrong S, Döhner K, Fischer T, Heidel FH.
Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo.
Leukemia. 2016 May;30(5):1220-5. Imp.-Fact.:11,702

Huang K, Yang M, Pan Z, Heidel FH, Scherr M, Eder M, Fischer T, Büsche G, Welte K, von Neuhoff N, Ganser A, Li Z.
Leukemogenic potency of the novel FLT3-N676K mutant.
Ann Hematol. 2016 Apr;95(5):783-91. Imp.-Fact.:2,634

Jayavelu AK, Müller JP, Bauer R, Böhmer SA, Lässig J, Cerny-Reiterer S, Sperr WR, Valent P, Maurer B, Moriggl R, Schröder K, Shah AM, Fischer M, Scholl S, Barth J, Oellerich T, Berg T, Serve H, Frey S, Fischer T, Heidel FH, Böhmer FD.
NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD positive AML cells.
Leukemia. 2016 Feb;30(2):473-83. Epub 2015 Aug 26. Imp.-Fact.:11,702

Jost F, Rinke K, Fischer T, Schalk E, Sager S.
Optimum experimental design for patient specific mathematical leukopenia models.
IFAC-PapersOnLine 2016;49(26):344-349.

Lipka DB, Wagner MC, Dziadosz M, Fischer T.
Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT-ITD-positive leukemias.
Leukemia. 2016 May 24. Imp.-Fact.:12,104

Perner F, Schnöder TM, Ranjan S, Wolleschak D, Ebert C, Pils MC, Frey S, Polanetzki A, Fahldieck C, Schönborn U, Schraven B, Isermann B, Fischer T, Heidel FH.
Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function.
Leukemia. 2016 Apr;30(4):991-5. Imp.-Fact.:11,702

Perner F, Schnöder TM, Fischer T, Heidel FH.
Kinomics Screening Identifies Aberrant Phosphorylation of CDC25C in FLT3-ITD-positive AML.
Anticancer Res. 2016 Dec;36(12):6249-6258. Imp.-Fact.:1,826

Rinke K, Jost F, Findeisen R, Fischer T, Bartsch R. Schalk E, Sager, S
Parameter estimation for leukocyte dynamics after chemotherapy
IFAC-PapersOnLine - Frankfurt: Elsevier, Bd. 49.2016, 26, S. 44-49